In addition, LAMP1 glycosylation exhibits tumor-specific alterations in pancreatic (71) and breast cancers (72, 73), influencing extracellular matrix interactions, drug response, and tumor heterogeneity, suggesting its potential as a biomarker and functional modulator in cancer. This evidence concerns the gene LAMP1 and breast cancer.